These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32503311)

  • 1. Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling.
    Oury C; Maréchal P; Donis N; Hulin A; Hego A; Tridetti J; Nguyen ML; Dulgheru R; Fillet M; Nchimi A; Lancellotti P
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pergolide-associated valvular heart disease.
    Waller EA; Kaplan J
    Compr Ther; 2006; 32(2):94-101. PubMed ID: 16845152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug-induced valve heart disease].
    Tribouilloy C; Jobic Y
    Rev Prat; 2016 Oct; 66(8):874-880. PubMed ID: 30512542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology.
    Droogmans S; Franken PR; Garbar C; Weytjens C; Cosyns B; Lahoutte T; Caveliers V; Pipeleers-Marichal M; Bossuyt A; Schoors D; Van Camp G
    Eur Heart J; 2007 Sep; 28(17):2156-62. PubMed ID: 17636306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro.
    Capulli AK; MacQueen LA; O'Connor BB; Dauth S; Parker KK
    Cardiovasc Pathol; 2016; 25(4):316-324. PubMed ID: 27174867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced fibrotic valvular heart disease.
    Bhattacharyya S; Schapira AH; Mikhailidis DP; Davar J
    Lancet; 2009 Aug; 374(9689):577-85. PubMed ID: 19683643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valvular heart disease in patients taking pergolide.
    Pritchett AM; Morrison JF; Edwards WD; Schaff HV; Connolly HM; Espinosa RE
    Mayo Clin Proc; 2002 Dec; 77(12):1280-6. PubMed ID: 12479512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
    Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
    J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional insights into pergolide-associated valvular heart disease.
    Lanier WL
    Mayo Clin Proc; 2003 Jun; 78(6):684-6. PubMed ID: 12934776
    [No Abstract]   [Full Text] [Related]  

  • 13. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
    Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
    Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
    Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
    J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced sox9 function promotes heart valve calcification phenotypes in vivo.
    Peacock JD; Levay AK; Gillaspie DB; Tao G; Lincoln J
    Circ Res; 2010 Mar; 106(4):712-9. PubMed ID: 20056916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
    Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
    Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
    JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine.
    Roldan CA; Gill EA; Shively BK
    Am J Cardiol; 2000 Sep; 86(5):535-9. PubMed ID: 11009272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation.
    Krishnaswami A; Albers KB; Fross RD; Jang JJ; Berkheimer SB; Kwai Ben VC; Vandeneeden SK
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):276-80. PubMed ID: 22231899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.
    Baseman DG; O'Suilleabhain PE; Reimold SC; Laskar SR; Baseman JG; Dewey RB
    Neurology; 2004 Jul; 63(2):301-4. PubMed ID: 15277624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.